Does the media favor CLPT or HYPR?

In the previous week, Hyperfine had 4 more articles in the media than ClearPoint Neuro. MarketBeat recorded 9 mentions for Hyperfine and 5 mentions for ClearPoint Neuro. Hyperfine's average media sentiment score of 0.36 beat ClearPoint Neuro's score of 0.14 indicating that Hyperfine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ClearPoint Neuro 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hyperfine 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, CARL or HYPR?

Carlsmed has higher revenue and earnings than Hyperfine. Carlsmed is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Carlsmed $50.51M 7.42 -$29.63M -$1.43 N/A Hyperfine $11.40M 8.27 -$35.57M -$0.38 N/A

Is CARL or HYPR more profitable?

Carlsmed has a net margin of -57.42% compared to Hyperfine's net margin of -210.75%. Carlsmed's return on equity of -38.06% beat Hyperfine's return on equity. Company Net Margins Return on Equity Return on Assets Carlsmed -57.42% -38.06% -28.96% Hyperfine -210.75% -99.81% -64.95%

Does the media refer more to CARL or HYPR?

In the previous week, Carlsmed and Carlsmed both had 9 articles in the media. Carlsmed's average media sentiment score of 0.52 beat Hyperfine's score of 0.36 indicating that Carlsmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Carlsmed 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hyperfine 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, HYPR or ELMD?

Electromed has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hyperfine $11.40M 8.27 -$35.57M -$0.38 N/A Electromed $71.75M 4.91 $5.15M $1.17 36.39

Is HYPR or ELMD more profitable?

Electromed has a net margin of 11.34% compared to Hyperfine's net margin of -210.75%. Electromed's return on equity of 15.71% beat Hyperfine's return on equity. Company Net Margins Return on Equity Return on Assets Hyperfine -210.75% -99.81% -64.95% Electromed 11.34% 15.71% 13.37%

Does the media favor HYPR or ELMD?

In the previous week, Hyperfine had 8 more articles in the media than Electromed. MarketBeat recorded 9 mentions for Hyperfine and 1 mentions for Electromed. Electromed's average media sentiment score of 1.54 beat Hyperfine's score of 0.36 indicating that Electromed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperfine 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Electromed 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation & earnings, CV or HYPR?

CapsoVision has higher revenue and earnings than Hyperfine. CapsoVision is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CapsoVision $13.55M 24.63 -$25.32M -$2.34 N/A Hyperfine $11.40M 8.27 -$35.57M -$0.38 N/A

Is CV or HYPR more profitable?

CapsoVision has a net margin of -198.87% compared to Hyperfine's net margin of -210.75%. CapsoVision's return on equity of 0.00% beat Hyperfine's return on equity. Company Net Margins Return on Equity Return on Assets CapsoVision -198.87% N/A -136.03% Hyperfine -210.75% -99.81% -64.95%

Hyperfine (HYPR) Competitors

$0.95 -0.01 (-0.52%)

As of 04:00 PM Eastern

Compare

HYPR vs. MOBI, CLPT, CARL, ELMD, and CV

Should you buy Hyperfine stock or one of its competitors? Hyperfine's main competitors and comparable companies include Mobia Medical (MOBI), ClearPoint Neuro (CLPT), Carlsmed (CARL), Electromed (ELMD), and CapsoVision (CV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Hyperfine compare to Mobia Medical?

Mobia Medical (NASDAQ:MOBI) and Hyperfine (NASDAQ:HYPR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

Mobia Medical has a net margin of 0.00% compared to Hyperfine's net margin of -210.75%. Mobia Medical's return on equity of 0.00% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mobia Medical	N/A	N/A	N/A
Hyperfine	-210.75%	-99.81%	-64.95%

In the previous week, Hyperfine had 9 more articles in the media than Mobia Medical. MarketBeat recorded 9 mentions for Hyperfine and 0 mentions for Mobia Medical. Hyperfine's average media sentiment score of 0.36 beat Mobia Medical's score of 0.00 indicating that Hyperfine is being referred to more favorably in the news media.

Company	Overall Sentiment
Mobia Medical	Neutral
Hyperfine	Neutral

15.0% of Hyperfine shares are held by institutional investors. 26.3% of Hyperfine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Hyperfine has lower revenue, but higher earnings than Mobia Medical. Hyperfine is trading at a lower price-to-earnings ratio than Mobia Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mobia Medical	$32.04M	13.21	-$46.50M	-$19.30	N/A
Hyperfine	$11.40M	8.27	-$35.57M	-$0.38	N/A

Mobia Medical presently has a consensus target price of $20.25, suggesting a potential upside of 59.07%. Hyperfine has a consensus target price of $1.74, suggesting a potential upside of 82.89%. Given Hyperfine's higher possible upside, analysts plainly believe Hyperfine is more favorable than Mobia Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mobia Medical	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Mobia Medical beats Hyperfine on 8 of the 15 factors compared between the two stocks.

How does Hyperfine compare to ClearPoint Neuro?

ClearPoint Neuro (NASDAQ:CLPT) and Hyperfine (NASDAQ:HYPR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

ClearPoint Neuro has higher revenue and earnings than Hyperfine. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	12.02	-$25.54M	-$1.18	N/A
Hyperfine	$11.40M	8.27	-$35.57M	-$0.38	N/A

ClearPoint Neuro currently has a consensus price target of $25.67, indicating a potential upside of 76.16%. Hyperfine has a consensus price target of $1.74, indicating a potential upside of 82.89%. Given Hyperfine's higher probable upside, analysts plainly believe Hyperfine is more favorable than ClearPoint Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

ClearPoint Neuro has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, Hyperfine has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market.

In the previous week, Hyperfine had 4 more articles in the media than ClearPoint Neuro. MarketBeat recorded 9 mentions for Hyperfine and 5 mentions for ClearPoint Neuro. Hyperfine's average media sentiment score of 0.36 beat ClearPoint Neuro's score of 0.14 indicating that Hyperfine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ClearPoint Neuro	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hyperfine	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

ClearPoint Neuro has a net margin of -81.76% compared to Hyperfine's net margin of -210.75%. Hyperfine's return on equity of -99.81% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-81.76%	-188.09%	-40.88%
Hyperfine	-210.75%	-99.81%	-64.95%

30.1% of ClearPoint Neuro shares are held by institutional investors. Comparatively, 15.0% of Hyperfine shares are held by institutional investors. 6.9% of ClearPoint Neuro shares are held by company insiders. Comparatively, 26.3% of Hyperfine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Hyperfine beats ClearPoint Neuro on 9 of the 15 factors compared between the two stocks.

How does Hyperfine compare to Carlsmed?

Carlsmed (NASDAQ:CARL) and Hyperfine (NASDAQ:HYPR) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

Carlsmed has higher revenue and earnings than Hyperfine. Carlsmed is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carlsmed	$50.51M	7.42	-$29.63M	-$1.43	N/A
Hyperfine	$11.40M	8.27	-$35.57M	-$0.38	N/A

In the previous week, Carlsmed and Carlsmed both had 9 articles in the media. Carlsmed's average media sentiment score of 0.52 beat Hyperfine's score of 0.36 indicating that Carlsmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Carlsmed	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hyperfine	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Carlsmed has a net margin of -57.42% compared to Hyperfine's net margin of -210.75%. Carlsmed's return on equity of -38.06% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carlsmed	-57.42%	-38.06%	-28.96%
Hyperfine	-210.75%	-99.81%	-64.95%

Carlsmed presently has a consensus target price of $19.25, indicating a potential upside of 40.20%. Hyperfine has a consensus target price of $1.74, indicating a potential upside of 82.89%. Given Hyperfine's higher probable upside, analysts plainly believe Hyperfine is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

15.0% of Hyperfine shares are owned by institutional investors. 12.9% of Carlsmed shares are owned by company insiders. Comparatively, 26.3% of Hyperfine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Carlsmed beats Hyperfine on 8 of the 14 factors compared between the two stocks.

How does Hyperfine compare to Electromed?

Hyperfine (NASDAQ:HYPR) and Electromed (NYSE:ELMD) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

Hyperfine currently has a consensus price target of $1.74, suggesting a potential upside of 82.89%. Electromed has a consensus price target of $37.50, suggesting a potential downside of 11.93%. Given Hyperfine's higher possible upside, analysts clearly believe Hyperfine is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Electromed has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40M	8.27	-$35.57M	-$0.38	N/A
Electromed	$71.75M	4.91	$5.15M	$1.17	36.39

Hyperfine has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Comparatively, Electromed has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

In the previous week, Hyperfine had 8 more articles in the media than Electromed. MarketBeat recorded 9 mentions for Hyperfine and 1 mentions for Electromed. Electromed's average media sentiment score of 1.54 beat Hyperfine's score of 0.36 indicating that Electromed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperfine	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Electromed	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

15.0% of Hyperfine shares are owned by institutional investors. Comparatively, 40.8% of Electromed shares are owned by institutional investors. 26.3% of Hyperfine shares are owned by insiders. Comparatively, 10.5% of Electromed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Electromed has a net margin of 11.34% compared to Hyperfine's net margin of -210.75%. Electromed's return on equity of 15.71% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-210.75%	-99.81%	-64.95%
Electromed	11.34%	15.71%	13.37%

Summary

Electromed beats Hyperfine on 10 of the 15 factors compared between the two stocks.

How does Hyperfine compare to CapsoVision?

CapsoVision (NASDAQ:CV) and Hyperfine (NASDAQ:HYPR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

CapsoVision has a net margin of -198.87% compared to Hyperfine's net margin of -210.75%. CapsoVision's return on equity of 0.00% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-198.87%	N/A	-136.03%
Hyperfine	-210.75%	-99.81%	-64.95%

15.0% of Hyperfine shares are held by institutional investors. 2.3% of CapsoVision shares are held by insiders. Comparatively, 26.3% of Hyperfine shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CapsoVision currently has a consensus target price of $8.50, indicating a potential upside of 27.25%. Hyperfine has a consensus target price of $1.74, indicating a potential upside of 82.89%. Given Hyperfine's higher possible upside, analysts plainly believe Hyperfine is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

CapsoVision has higher revenue and earnings than Hyperfine. CapsoVision is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.55M	24.63	-$25.32M	-$2.34	N/A
Hyperfine	$11.40M	8.27	-$35.57M	-$0.38	N/A

In the previous week, Hyperfine had 9 more articles in the media than CapsoVision. MarketBeat recorded 9 mentions for Hyperfine and 0 mentions for CapsoVision. Hyperfine's average media sentiment score of 0.36 beat CapsoVision's score of 0.00 indicating that Hyperfine is being referred to more favorably in the news media.

Company	Overall Sentiment
CapsoVision	Neutral
Hyperfine	Neutral

Summary

Hyperfine beats CapsoVision on 9 of the 16 factors compared between the two stocks.

Get Hyperfine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HYPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HYPR vs. The Competition

Export

Metric	Hyperfine	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$94.80M	$5.82B	$7.02B	$12.98B
Dividend Yield	N/A	1.78%	2.58%	10.20%
P/E Ratio	-2.50	20.21	210.34	20.96
Price / Sales	8.27	61.03	588.78	86.31
Price / Cash	N/A	33.55	28.89	37.42
Price / Book	2.26	6.21	11.27	6.42
Net Income	-$35.57M	$147.87M	$3.45B	$347.03M
7 Day Performance	-3.18%	3.40%	3.56%	2.48%
1 Month Performance	-12.84%	1.66%	-0.58%	-1.04%
1 Year Performance	-18.10%	6.26%	77.52%	23.22%

Hyperfine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HYPR Hyperfine	3.1882 of 5 stars	$0.95 -0.5%	$1.74 +82.9%	-17.7%	$94.80M	$11.40M	N/A	190	Earnings Report Analyst Forecast
MOBI Mobia Medical	4.5493 of 5 stars	$11.84 +4.3%	$20.25 +71.0%	N/A	$393.67M	$38.45M	N/A	N/A
CLPT ClearPoint Neuro	2.6487 of 5 stars	$12.88 -16.3%	$25.67 +99.3%	+31.3%	$386.27M	$36.97M	N/A	110	Earnings Report Analyst Downgrade High Trading Volume
CARL Carlsmed	1.953 of 5 stars	$13.43 +3.9%	$18.75 +39.6%	N/A	$365.10M	$56.44M	N/A	100	Earnings Report
ELMD Electromed	1.2192 of 5 stars	$42.16 +1.4%	$37.50 -11.1%	+126.3%	$349.09M	$71.75M	56.21	160	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HYPR) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hyperfine (HYPR) Competitors

HYPR vs. MOBI, CLPT, CARL, ELMD, and CV

How does Hyperfine compare to Mobia Medical?

Summary

How does Hyperfine compare to ClearPoint Neuro?

Summary

How does Hyperfine compare to Carlsmed?

Summary

How does Hyperfine compare to Electromed?

Summary

How does Hyperfine compare to CapsoVision?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYPR vs. The Competition

Hyperfine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hyperfine (HYPR) Competitors

HYPR vs. MOBI, CLPT, CARL, ELMD, and CV

How does Hyperfine compare to Mobia Medical?

Is MOBI or HYPR more profitable?

Does the media prefer MOBI or HYPR?

Do insiders & institutionals have more ownership in MOBI or HYPR?

Which has stronger valuation & earnings, MOBI or HYPR?

Do analysts prefer MOBI or HYPR?

Summary

How does Hyperfine compare to ClearPoint Neuro?

Which has better earnings & valuation, CLPT or HYPR?

Do analysts prefer CLPT or HYPR?

Which has more volatility and risk, CLPT or HYPR?

Does the media favor CLPT or HYPR?

Is CLPT or HYPR more profitable?

Do institutionals and insiders hold more shares of CLPT or HYPR?

Summary

How does Hyperfine compare to Carlsmed?

Which has preferable earnings and valuation, CARL or HYPR?

Does the media refer more to CARL or HYPR?

Is CARL or HYPR more profitable?

Do analysts recommend CARL or HYPR?

Do institutionals and insiders have more ownership in CARL or HYPR?

Summary

How does Hyperfine compare to Electromed?

Do analysts rate HYPR or ELMD?

Which has better valuation and earnings, HYPR or ELMD?

Which has more risk and volatility, HYPR or ELMD?

Does the media favor HYPR or ELMD?

Do insiders & institutionals hold more shares of HYPR or ELMD?

Is HYPR or ELMD more profitable?

Summary

How does Hyperfine compare to CapsoVision?

Is CV or HYPR more profitable?

Do insiders & institutionals hold more shares of CV or HYPR?

Do analysts recommend CV or HYPR?

Which has better valuation & earnings, CV or HYPR?

Does the media favor CV or HYPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYPR vs. The Competition

Hyperfine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools